Literature DB >> 34531296

Decoding the Cardiac Actions of Protein Kinase D Isoforms.

Susan F Steinberg1.   

Abstract

Protein kinase D (PKD) consists of a family of three structurally related enzymes that play key roles in a wide range of biological functions that contribute to the evolution of cardiac hypertrophy and heart failure. PKD1 (the founding member of this enzyme family) has been implicated in the phosphorylation of substrates that regulate cardiac hypertrophy, contraction, and susceptibility to ischemia/reperfusion injury, and de novo PRKD1 (protein kinase D1 gene) mutations have been identified in patients with syndromic congenital heart disease. However, cardiomyocytes coexpress all three PKDs. Although stimulus-specific activation patterns for PKD1, PKD2, and PKD3 have been identified in cardiomyocytes, progress toward identifying PKD isoform-specific functions in the heart have been hampered by significant gaps in our understanding of the molecular mechanisms that regulate PKD activity. This review incorporates recent conceptual breakthroughs in our understanding of various alternative mechanisms for PKD activation, with an emphasis on recent evidence that PKDs activate certain effector responses as dimers, to consider the role of PKD isoforms in signaling pathways that drive cardiac hypertrophy and ischemia/reperfusion injury. The focus is on whether the recently identified activation mechanisms that enhance the signaling repertoire of PKD family enzymes provide novel therapeutic strategies to target PKD enzymes and prevent or slow the evolution of cardiac injury and pathological cardiac remodeling. SIGNIFICANCE STATEMENT: PKD isoforms regulate a large number of fundamental biological processes, but the understanding of the biological actions of individual PKDs (based upon studies using adenoviral overexpression or gene-silencing methods) remains incomplete. This review focuses on dimerization, a recently identified mechanism for PKD activation, and the notion that this mechanism provides a strategy to develop novel PKD-targeted pharmaceuticals that restrict proliferation, invasion, or angiogenesis in cancer and prevent or slow the evolution of cardiac injury and pathological cardiac remodeling.
Copyright © 2021 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34531296      PMCID: PMC8626784          DOI: 10.1124/molpharm.121.000341

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  82 in total

1.  Protein kinase D activation induces mitochondrial fragmentation and dysfunction in cardiomyocytes.

Authors:  Bong Sook Jhun; Jin O-Uchi; Stephanie M Adaniya; Thomas J Mancini; Jessica L Cao; Michelle E King; Amy K Landi; Hanley Ma; Milla Shin; Donqin Yang; Xiaole Xu; Yisang Yoon; Gaurav Choudhary; Richard T Clements; Ulrike Mende; Shey-Shing Sheu
Journal:  J Physiol       Date:  2018-01-25       Impact factor: 5.182

Review 2.  Regulation of protein kinase D1 activity.

Authors:  Susan F Steinberg
Journal:  Mol Pharmacol       Date:  2011-12-21       Impact factor: 4.436

Review 3.  Protein kinase D signaling: multiple biological functions in health and disease.

Authors:  Enrique Rozengurt
Journal:  Physiology (Bethesda)       Date:  2011-02

4.  Protein kinase D isoforms are activated in an agonist-specific manner in cardiomyocytes.

Authors:  Jianfen Guo; Zoya Gertsberg; Nazira Ozgen; Abdelkarim Sabri; Susan F Steinberg
Journal:  J Biol Chem       Date:  2010-12-14       Impact factor: 5.157

5.  Proteolytic cleavage and activation of protein kinase C [micro] by caspase-3 in the apoptotic response of cells to 1-beta -D-arabinofuranosylcytosine and other genotoxic agents.

Authors:  K Endo; E Oki; V Biedermann; H Kojima; K Yoshida; F J Johannes; D Kufe; R Datta
Journal:  J Biol Chem       Date:  2000-06-16       Impact factor: 5.157

6.  Characterization of a novel protein kinase D: Caenorhabditis elegans DKF-1 is activated by translocation-phosphorylation and regulates movement and growth in vivo.

Authors:  Hui Feng; Min Ren; Shi-Lan Wu; David H Hall; Charles S Rubin
Journal:  J Biol Chem       Date:  2006-04-13       Impact factor: 5.157

7.  Potent and selective disruption of protein kinase D functionality by a benzoxoloazepinolone.

Authors:  Elizabeth R Sharlow; Karthik V Giridhar; Courtney R LaValle; Jun Chen; Stephanie Leimgruber; Rebecca Barrett; Karla Bravo-Altamirano; Peter Wipf; John S Lazo; Q Jane Wang
Journal:  J Biol Chem       Date:  2008-09-30       Impact factor: 5.157

8.  Sequential protein kinase C (PKC)-dependent and PKC-independent protein kinase D catalytic activation via Gq-coupled receptors: differential regulation of activation loop Ser(744) and Ser(748) phosphorylation.

Authors:  Rodrigo Jacamo; James Sinnett-Smith; Osvaldo Rey; Richard T Waldron; Enrique Rozengurt
Journal:  J Biol Chem       Date:  2008-03-12       Impact factor: 5.157

9.  Monophosphorylation of cardiac troponin-I at Ser-23/24 is sufficient to regulate cardiac myofibrillar Ca2+ sensitivity and calpain-induced proteolysis.

Authors:  Abel Martin-Garrido; Brandon J Biesiadecki; Hussam E Salhi; Yasin Shaifta; Cristobal G Dos Remedios; Serife Ayaz-Guner; Wenxuan Cai; Ying Ge; Metin Avkiran; Jonathan C Kentish
Journal:  J Biol Chem       Date:  2018-04-18       Impact factor: 5.157

Review 10.  Mechanisms for redox-regulation of protein kinase C.

Authors:  Susan F Steinberg
Journal:  Front Pharmacol       Date:  2015-06-23       Impact factor: 5.810

View more
  1 in total

1.  Low-Dose Anti-HIV Drug Efavirenz Mitigates Retinal Vascular Lesions in a Mouse Model of Alzheimer's Disease.

Authors:  Nicole El-Darzi; Natalia Mast; David A Buchner; Aicha Saadane; Brian Dailey; Georgios Trichonas; Irina A Pikuleva
Journal:  Front Pharmacol       Date:  2022-06-01       Impact factor: 5.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.